Conditioning regimen with Flu/Bu4/Mel vs conventional myeloablative conditioning improves survival in R/R AML patients in non-remission

Key clinical point: A myeloablative conditioning regimen consisting of fludarabine, a myeloablative dose of intravenous busulfan, and melphalan (Flu/Bu4/Mel) vs conventional myeloablative conditioning regimen (cMAC) before allogeneic hematopoietic stem cell transplantation resulted in improved prognosis in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) in non-remission.

Major finding: Flu/Bu4/Mel vs cMAC resulted in significantly improved 5-year overall survival (adjusted hazard ratio [aHR], 0.57; P = .015), relapse (aHR, 0.64; P = .031), and relapse-associated mortality (aHR, 0.64; P = .043).

Study details: This study assessed the prognostic impact of Flu/Bu4/Mel (n=94) vs cMAC (n=94) in 188 adult patients with R/R AML in non-remission.

Disclosures: No specific source of funding was identified. The authors declared no conflicts of interest.

Source: Shimomura Y et al. Bone Marrow Transplant. 2021 Jun 21. doi: 10.1038/s41409-021-01380-0.

Key clinical point: A myeloablative conditioning regimen consisting of fludarabine, a myeloablative dose of intravenous busulfan, and melphalan (Flu/Bu4/Mel) vs conventional myeloablative conditioning regimen (cMAC) before allogeneic hematopoietic stem cell transplantation resulted in improved prognosis in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) in non-remission.

Major finding: Flu/Bu4/Mel vs cMAC resulted in significantly improved 5-year overall survival (adjusted hazard ratio [aHR], 0.57; P = .015), relapse (aHR, 0.64; P = .031), and relapse-associated mortality (aHR, 0.64; P = .043).

Study details: This study assessed the prognostic impact of Flu/Bu4/Mel (n=94) vs cMAC (n=94) in 188 adult patients with R/R AML in non-remission.

Disclosures: No specific source of funding was identified. The authors declared no conflicts of interest.

Source: Shimomura Y et al. Bone Marrow Transplant. 2021 Jun 21. doi: 10.1038/s41409-021-01380-0.

Key clinical point: A myeloablative conditioning regimen consisting of fludarabine, a myeloablative dose of intravenous busulfan, and melphalan (Flu/Bu4/Mel) vs conventional myeloablative conditioning regimen (cMAC) before allogeneic hematopoietic stem cell transplantation resulted in improved prognosis in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) in non-remission.

Major finding: Flu/Bu4/Mel vs cMAC resulted in significantly improved 5-year overall survival (adjusted hazard ratio [aHR], 0.57; P = .015), relapse (aHR, 0.64; P = .031), and relapse-associated mortality (aHR, 0.64; P = .043).

Study details: This study assessed the prognostic impact of Flu/Bu4/Mel (n=94) vs cMAC (n=94) in 188 adult patients with R/R AML in non-remission.

Disclosures: No specific source of funding was identified. The authors declared no conflicts of interest.

Source: Shimomura Y et al. Bone Marrow Transplant. 2021 Jun 21. doi: 10.1038/s41409-021-01380-0.